Login to Your Account

Financings Roundup

Achaogen's Series C Adds $56M to Push Early Stage Antibiotics

By Catherine Hollingsworth

Thursday, April 8, 2010
Achaogen completed a $56 million Series C financing that will allow the company to advance multiple clinical programs, including a Phase II study of lead candidate ACHN-490 in patients with complicated urinary tract infections (UTIs). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription